RT Journal Article SR Electronic T1 Recurrent SARS-CoV-2 Mutations in Immunodeficient Patients JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.03.02.22271697 DO 10.1101/2022.03.02.22271697 A1 Sam AJ Wilkinson A1 Alex Richter A1 Anna Casey A1 Husam Osman A1 Jeremy D Mirza A1 Joanne Stockton A1 Josh Quick A1 Liz Ratcliffe A1 Natalie Sparks A1 Nicola Cumley A1 Radoslaw Poplawski A1 Sam Nicholls A1 Beatrix Kele A1 Kathryn Harris A1 The COVID-19 Genomics UK (COG-UK) consortium A1 Thomas P Peacock A1 Nicholas J Loman YR 2022 UL http://medrxiv.org/content/early/2022/03/02/2022.03.02.22271697.abstract AB Long-term SARS-CoV-2 infections in immunodeficient patients are an important source of variation for the virus but are understudied. Many case studies have been published which describe one or a small number of long-term infected individuals but no study has combined these sequences into a cohesive dataset. This work aims to rectify this and study the genomics of this patient group through a combination of literature searches as well as identifying new case series directly from the COG-UK dataset. The spike gene receptor binding domain (RBD) and N-terminal domains (NTD) were identified as mutation hotspots. Numerous mutations associated with variants of concern were observed to emerge recurrently. Additionally a mutation in the envelope gene, - T30I was determined to be the most recurrent frequently occurring mutation arising in persistent infections. A high proportion of recurrent mutations in immunodeficient individuals are associated with ACE2 affinity, immune escape, or viral packaging optimisation.There is an apparent selective pressure for mutations which aid intra-host transmission or persistence which are often different to mutations which aid inter-host transmission, although the fact that multiple recurrent de novo mutations are considered defining for variants of concern strongly indicates that this potential source of novel variants should not be discounted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCOG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) [grant code: MC_PC_19027], and Genome Research Limited, operating as the Wellcome Sanger Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The COG-UK study protocol was approved by the Public Health England Research Ethics Governance Group (reference: R&D NR0195). Authors only had access to anonymised data. No individual patient consent was required.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data included in the present work are available online or upon reasonable request to the producing author. The full details of the data are available within the supplement. https://github.com/BioWilko/recurrent-sars-cov-2-mutations